Upper gastrointestinal endoscopy in systemic sclerosis: A cross sectional study
Keywords:
Acid regurgitation, dysphagia, esophageal symptoms, reflux esophagitis, systemic sclerosisAbstract
Background and Aims Involvement of the gastrointestinal tract is common in systemic sclerosis. The aim of this study was to identify the frequency and severity of dyspeptic symptoms in systemic sclerosis patients and to identify the common patterns of upper gastrointestinal endoscopic pathology from Kashmir valley, the study being first of its kind in the region. Methods Thirty seven sequential, newly and already diagnosed cases of systemic sclerosis were taken up for the study. This included 28 patients with limited systemic sclerosis and 9 patients with diffuse disease. They were enquired about the frequency and severity of symptoms of dysphagia, acid regurgitation and heartburn. Patients were then subjected to upper gastrointestinal endoscopy to identify abnormal findings. Results Esophageal symptoms were present in 26 (70.3%) patients. 17 (60.7%) patients with limited disease showed esophageal symptoms while all 9 (100%) patients with diffuse disease showed these symptoms (p=0.025). Upper gastrointestinal endoscopy showed abnormal findings in 23 (62.2%) patients. Esophagus was most frequently involved organ with abnormalities seen in 15 (40.5%) patients, followed by involvement of the stomach in 13 (35.1%) patients and the duodenum in 5 (13.5%) patients. Reflux esophagitis was the commonest abnormality, seen in 12 (32.4%). Conclusion Esophageal symptoms are a common occurrence in systemic sclerosis patients and seem to occur with a greater frequency in the diffuse disease subset. There seems to be no statistical difference between the two disease subsets in terms of the severity of the symptoms. Esophagitis appears to be the most common finding on upper gastrointestinal endoscopy.References
Orteu CH, Denton CP. Systemic Sclerosis. In: Griffiths CEM, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Rook’s textbook of dermatology. 9th ed. West Sussex (UK);Wiley Blackwell: 2016.p.56.1-23.
Hansi N, Thoua N, Carulli M, et al. Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clin Exp Rheumatol. 2014; 32(6 Suppl 86): S214-21.
Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am. 1998; 27: 563-94.
Poirier TJ, Rankin GB. Gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases. Am J Gastroenterol. 1972; 58: 30-44.
Orringer MB, Dabich L, Zarafonetis CJ, Sloan H. Gastroesophageal reflux in esophageal scleroderma: diagnosis and implications. Ann Thorac Surg. 1976; 22: 120-30.
Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994; 37: 1265-82.
Ebert EC. Esophageal disease in scleroderma. J Clin Gastroenterol. 2006; 40: 769–775.DOI: 10.1097/01.mcg.0000225549.19127.90.
Ntoumazios SK, Voulgari PV, Potsis K, Koutis E, Tsifetaki N, Assimakopoulos DA. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum. 2006; 36: 173-81.
doi: 10.1016/j.semarthrit.2006.08.002.
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980; 23: 58-90.
Le Roy EC, Black C, Fleischmajer R. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15: 202-5.
Dombal FT, Hall R. The evaluation of medical care from the clinician’s point of view, what should we measure, and can we trust our measurements ? In evaluation of efficacy of medical action. Amsterdam: Elsevier-North Holland; 1979: 13-29.
Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterol. 1996; 111: 85-92.
Lundell L, Dent J, Bennett J, et al. Endoscopic assessment of esophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999; 45: 172-80.
Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29: 139-54.
Silver RM. Clinical aspects of systemic sclerosis. Ann Rheum Dis. 1991; 50: 854-61.
Laing TJ, Gillespie BW, Toth MB, et al . Racial differences in scleroderma among women in Michigan. Arthritis Rheum. 1997; 40: 734-42.
Sharma VK, Trilokraj T, Khaitan BK, Krishna SM. Profile of systemic sclerosis in a tertiary care center in North India. Indian J Dermatol Venereol Leprol. 2006; 72: 416-20.
Medsger TA, Masi AT. Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med. 1971; 74: 714-21.
Ruangjutipopan S, Kasitanon N, Louthrenoo W, Sukitawut W, Wichainun R. Causes of death and poor survival prognostic factors in Thai patients with systemic sclerosis. J Med Assoc Thai. 2002; 85: 1204-9.
Krishnamurthy V, Porkodi R, Ramakrishnan S, et al . Progressive systemic sclerosis in south India. J Assoc Physics India. 1991; 39: 254-7.
Christianson HB, Dorsey CS, Kierland RR, O’Leary PA. Localized scleroderma: a clinical study of 235 cases. Arch Dermatol. 1956; 74: 629-39.
Lahcene M, Oumnia N, Matougui N, Boudjella M, Tebaibia A, Touchene B. Esophageal involvement in scleroderma: Clinical, Endoscopic, and Manometric Features. ISRN Rheumatol. 2011; 2011: 1-5. Article id: 325826. doi:10.5402/2011/325826.
Kinuya K, Nakajima K, Kinuya S, Michigishi T, Tonami N, Takehara K. Esophageal hypomotility in systemic sclerosis: close relationship with pulmonary involvement. Ann Nuclear Med. 2001; 15: 97-101.
Tuffanelli DL, Winkelman RK. Systemic scleroderma: a clinical study of 727 cases. Arch Dermatol. 1961; 84: 359-67.
Lock G, Holstege A, Lang B, Scholmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol. 1997;92:763-71.
Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am. 1998; 27: 563-94.
Abu-Shakra M, Guillemin F, Lee P. Gastro-intestinal manifestations of systemic sclerosis. Semin Arthritis Rheum. 1994; 24: 29-39.
Aubert A, Lazareth I, Vayssairat M, Fiessinger JN, Petite JP. L'oesophagite au cours de la sclérodermiesystémique. Prévalence-et-facteurs de survenue chez 46 patients. Gastroenterol Clin Biol. 1991; 15: 945-9.
Turner R, Lipshutz W, Miller W, Rittenberg G, Schumacher HR, Cohen S. Esophageal dysfunction in colllagen disease. Am J Med Sci. 1973; 265: 191-9.
Poirier TJ, Ranklin GB. Gastrointestinal manifestation of progressive systemic scleroderma based on a review of 364 cases. Am J Gastroenterol. 1972; 58: 30-44.
Airo P, Case DD, Danieli E, Missale G, Cattaneo R, Cestari R. Oesophageal manometry in early and definite systemic sclerosis. Clin Rheumatol. 2005; 24: 370-6.
Ostojić P, Damjanov N. Different clinical features in patients with limited and diffuse systemic sclerosis. Clin Rheumatol. 2006; 25: 453-7.
Bassotti G, Battaglia E, Debernardi V, et al. Esophageal dysfunction in scleroderma. Relationship with disease subsets. Arthritis Rheum. 1997; 40: 2252-9.
Wegener M, Adamek RJ, Wedmann B, Jergas M, Altmeyer P. Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. Dig Dis Sci. 1994; 39: 2209-15.
Koshino Y, Takai T, Kato T, et al. Manometric evaluation of esophageal function in progressive systemic sclerosis with special regard to the disease severity. Gastroenterol Jpn. 1991; 26: 575-81.
Calderaro DC, de carvalho MAP, Moretzsohn LD. Esophageal manometry in 28 systemic sclerosis Brazilian patients: findings and correlations. Diseases of the Esophagus. 2009; 22: 700-4.
Arif T, Masood Q, Singh J, Hassan I. Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study. BMC Gastroenterol. 2015; 15:24.
Marie I, Ducrotté P, Denis P, Hellot MF, Levesque H. Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006; 24: 1593-601.
Poirer TJ, Rankin GB. gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases. Am J Gastroenterol. 1972; 58: 30-44.
Hendel L. Esophageal and small intestinal manifestations of progressive systemic sclerosis. Danish Medical Bulletin. 1994; 41: 371-85.
Wipff J, Allanore Y, Soussi F, et al. Prevalence of Barret’s esophagus in systemic sclerosis. Arthritis Rheum. 2005; 52: 2882-8.
Ebert EC. Esophageal disease in scleroderma. J Clin Gastroenterol. 2006; 40: 769-75.
Segel MC, Campbell WL, Medsger TA, Roumm AD. Systemic sclerosis (scleroderma) and esophageal carcinoma: is increased patient screening necessary. Gastroenterol. 1985; 89: 485-8.
Duchini A, Sessoms SL. Gastrointestinal hemorrhage in patients with systemic sclerosis and CREST syndrome. Am J Gastroenterol. 1998; 93: 1453-6.
Thonhofer R, Siegel C, Trummer M, Graninger W. Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol International. 2012; 32: 165-8.
Parrado RH, Lemus HN, Coral-Alvarado PX, Quintana G. Gastric antral vascular ectasia in systemic sclerosis: current concepts. Int J Rheumatol. 2015; 2015: 762546. doi:10.1155/2015/762546.
Marie I, Ducrotte P, Antonietti M, Herve S, Levesque H. Watermelon stomach in systemic sclerosis: its incidence and management. Aliment Pharmacol Ther. 2008; 28: 412-21.
Selinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. Digestion. 2008; 77: 131-7.
Dalle I, Giboes K. Vascular lesions of the gastrointestinal tract. Acta Gastroenterol Belg 2002;65:213-9.
El-Omar MM, Jenkins AP, Hollowood K, Banerjee AK, Thompson RPH. Gastric telangiectasis: a rare cause of severe blood loss in CREST syndrome. Postgrad Med J 1994; 70: 302-4.
Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology 2009 (Suppl 3); 48:iii36-9.
Sallam H, McNearny TA, Chen JZ. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther. 2006; 23: 691-712.
Sodhi JS, Javid G, Zargar SA, et al. Prevalence of Helicobacter pylori infection and the effect of its eradication on symptoms of functional dyspepsia in Kashmir, India. J Gastroenterol Hepatol. 2013; 28: 808-13.
